Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.

Neal D ShoreFrançois LalibertéRaluca Ionescu-IttuLingfeng YangMalena MahendranDominique LejeuneLouise H YuJoseph BurgentsMei Sheng DuhSameer R Ghate

Published in: Advances in therapy (2021)

NHA were widely used as 1L therapy in mCRPC patients from 2013 to 2019, but time on 1L NHA treatment was on average < 6 months. While NHA → NHA was the most observed 1L → 2L LOT sequence, a plethora of other LOT sequences were observed. OS was poor, highlighting an unmet need for life-prolonging treatments.

Keyphrases

end stage renal disease
ejection fraction
dna damage
prognostic factors
peritoneal dialysis
dna repair
patient reported outcomes
combination therapy
replacement therapy